A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

Locations

Germany

Start date

18/05/2026

Identifiers

Trial ID NN9833-8285,
NCT number NCT07597018,
Eudract number Not Available

Summary

This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide version D or cagrilintide version B, and which treatment participants receive is decided by chance. Participants will be in this clinical study for about 6 months.

Trial Overview:

Condition

Obesity

Overweight

Treatment

DRUG: Cagrilintide D

DRUG: Cagrilintide B and placebo semaglutide I

Study type

INTERVENTIONAL

Trial duration

May 18 2026 - Jun 01 2027

Participants

234

Phase

Are you eligible?

Gender

Male and female

Age

18 to 64 years old

Find out how you can participate

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.